| 16.1 -0.54 (-3.25%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.99  |
1-year : | 26.2 |
| Resists | First : | 18.83 |
Second : | 22.44 |
| Pivot price | 14.75  |
|||
| Supports | First : | 12.98 | Second : | 10.8 |
| MAs | MA(5) : | 15.76 |
MA(20) : | 14.85 |
| MA(100) : | 23.09 |
MA(250) : | 12.96 |
|
| MACD | MACD : | -1.1 |
Signal : | -1.7 |
| %K %D | K(14,3) : | 83.3 |
D(3) : | 76.5 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 36.25 | Low : | 3.29 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OLMA ] has closed below upper band by 12.9%. Bollinger Bands are 64.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 16.91 - 17 | 17 - 17.05 |
| Low: | 15.58 - 15.69 | 15.69 - 15.76 |
| Close: | 15.94 - 16.11 | 16.11 - 16.21 |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Sat, 11 Apr 2026
Olema Pharmaceuticals (NASDAQ:OLMA) Raised to "Sell" at Wall Street Zen - MarketBeat
Mon, 06 Apr 2026
SG Americas Securities LLC Purchases Shares of 69,382 Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Thu, 02 Apr 2026
Four new Olema hires receive stock options for 188,500 shares - Stock Titan
Thu, 02 Apr 2026
OLMA Stock Price, Quote & Chart | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
Thu, 19 Mar 2026
Olema Pharmaceuticals (OLMA) Is Down 6.7% After Posting Wider Losses And Filing New Stock Shelf - simplywall.st
Wed, 18 Mar 2026
LifeSci Capital reiterates a buy on Olema Pharmaceuticals (OLMA) - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 87 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 101.2 (%) |
| Shares Short | 8,240 (K) |
| Shares Short P.Month | 9,000 (K) |
| EPS | -1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.5 % |
| Return on Equity (ttm) | -36.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -147 (M) |
| Levered Free Cash Flow | -83 (M) |
| PE Ratio | -8.61 |
| PEG Ratio | 0 |
| Price to Book value | 2.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|